Dr. Kipps is talking about some of the potential of ROR1 in this ASH 2018 interview: cllsociety.org/2019/04/ash-...
Dr. Wiestner's team in Bethesda is conducting a very innovative trial for high risk CLL. Well worth considering if you are a good fit. Here is our Q+A about it: cllsociety.org/2019/04/high...
Brian, Dr. Wiestner is great. I go to the NIH and have the most pleasant experience. They sit, and take time with you. Listen to all your concerns. Just a great staff and place. I have never regretted about signing up for their study. STAY STRONG JR. 😊😊
My CLL and CAR-T story
Results on triple combination (A+V+O) for high risk patients -with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cllASH 2018: ECOG trial shows superiority of Ibrutinib and rituximab over FCRNews about V+O and Acalabrutinib from EHAVaccines, Ibrutinib toxicity,Dr. Rai on a cure, Dr Ghia on TP563 testing and ERIC
